Chinese Online Healthcare Platforms' Growth Could Normalize This Year -- Market Talk

Dow Jones

Feb 10

0912 GMT - Strong growth posted by Chinese online healthcare platforms in the past two years could be softer this year, though it's unlikely to be a concern for Alibaba Health Information Technology and JD Health, say HSBC analysts in a note. Online platforms have been gaining drug sales market share as more sales are taking place outside of hospitals, they say. They expect the prescription outflow to sustain growth for these platforms. HSBC lifts its target price for Alibaba Health to HK$6.50 from HK$6.00, but maintains a hold rating as its current valuation has priced in the company's recent artificial-intelligence developments. It raises its target price for JD Health to HK$77.50 from HK$75.50 on updated foreign exchange updates and retains a buy rating. Alibaba Health closed at HK$6.14 while JD Health ended at HK$60.25. (megan.cheah@wsj.com)

(END) Dow Jones Newswires

February 10, 2026 04:12 ET (09:12 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610610220"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610610220\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610610220?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-10 17:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610610220","market":"nz","top_or_hot":-1,"title":"Chinese Online Healthcare Platforms' Growth Could Normalize This Year -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0912 GMT - Strong growth posted by Chinese online healthcare platforms in the past two years could be softer this year, though it's unlikely to be a concern for <a href=\"https://laohu8.com/S/ALBBY\">Alibaba Health Information</a> Technology and <a href=\"https://laohu8.com/S/JD\">JD</a> Health, say <a href=\"https://laohu8.com/S/HSBC\">HSBC</a> analysts in a note. Online platforms have been gaining drug sales market share as more sales are taking place outside of hospitals, they say. They expect the prescription outflow to sustain growth for these platforms. HSBC lifts its target price for Alibaba Health to HK$6.50 from HK$6.00, but maintains a hold rating as its current valuation has priced in the company's recent artificial-intelligence developments. It raises its target price for JD Health to HK$77.50 from HK$75.50 on updated foreign exchange updates and retains a buy rating. Alibaba Health closed at HK$6.14 while JD Health ended at HK$60.25. (megan.cheah@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 10, 2026 04:12 ET (09:12 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese Online Healthcare Platforms' Growth Could Normalize This Year -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese Online Healthcare Platforms' Growth Could Normalize This Year -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-10 17:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0912 GMT - Strong growth posted by Chinese online healthcare platforms in the past two years could be softer this year, though it's unlikely to be a concern for <a href=\"https://laohu8.com/S/ALBBY\">Alibaba Health Information</a> Technology and <a href=\"https://laohu8.com/S/JD\">JD</a> Health, say <a href=\"https://laohu8.com/S/HSBC\">HSBC</a> analysts in a note. Online platforms have been gaining drug sales market share as more sales are taking place outside of hospitals, they say. They expect the prescription outflow to sustain growth for these platforms. HSBC lifts its target price for Alibaba Health to HK$6.50 from HK$6.00, but maintains a hold rating as its current valuation has priced in the company's recent artificial-intelligence developments. It raises its target price for JD Health to HK$77.50 from HK$75.50 on updated foreign exchange updates and retains a buy rating. Alibaba Health closed at HK$6.14 while JD Health ended at HK$60.25. (megan.cheah@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 10, 2026 04:12 ET (09:12 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0918141887.USD","symbol_name":"安联亚洲实际收益股票基金","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2610610220","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610610220","pubTimestamp":1770714720,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0912 GMT - Strong growth posted by Chinese online healthcare platforms in the past two years could be softer this year, though it's unlikely to be a concern for Alibaba Health Information Technology and JD Health, say HSBC analysts in a note. Online platforms have been gaining drug sales market share as more sales are taking place outside of hospitals, they say. They expect the prescription outflow to sustain growth for these platforms. HSBC lifts its target price for Alibaba Health to HK$6.50 from HK$6.00, but maintains a hold rating as its current valuation has priced in the company's recent artificial-intelligence developments. It raises its target price for JD Health to HK$77.50 from HK$75.50 on updated foreign exchange updates and retains a buy rating. Alibaba Health closed at HK$6.14 while JD Health ended at HK$60.25. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"86618":"京东健康-R","LU0918141887.USD":"安联亚洲实际收益股票基金","SGXZ62798434.SGD":"MAYBANK ASIAN GROWTH AND INCOME-I \"A\" (SGDHDG) ACC","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","BK4554":"元宇宙及AR概念","BK1584":"蚂蚁金服概念","LU0348814723.USD":"ALLIANZ TOTAL RETURN ASIAN EQUITY \"A\" (USD) INC  NC","BK1571":"互联网医疗","BK4585":"ETF&股票定投概念","00241":"阿里健康","BK1591":"就地过年概念","LU0251143458.SGD":"Fidelity Emerging Markets A-SGD","LU1046421795.USD":"富达环球科技A-ACC","BK1247":"药品零售","BK1583":"高瓴概念","BK4558":"双十一","BK4587":"ChatGPT概念","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","LU0651946864.USD":"贝莱德新兴市场股票收益A2","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","LU1051768304.USD":"贝莱德新兴市场股票收益A6","BK4588":"碎股","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","BK4565":"NFT概念","BABO":"BABA期权收益策略ETF-YieldMax","LU1515016050.SGD":"Blackrock Emerging Markets Equity Income A6 SGD-H","LU0456842615.SGD":"JPMorgan Funds - Emerging Markets Equity A (acc) SGD","BABW":"Roundhill BABA WeeklyPay ETF","BK1610":"ETF&股票定投概念","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","BABX":"2倍做多BABA ETF-GraniteShares","LU0545039389.USD":"BGF GLOBAL EQUITY INCOME \"A2\" ACC","LU1048596156.SGD":"Blackrock Asian Growth Leaders A2 SGD-H","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","HSBC":"汇丰","LU1046422090.SGD":"Fidelity Pacific A-SGD","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","BK4503":"景林资产持仓","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","BK4502":"阿里概念","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","BK4505":"高瓴资本持仓","BK4521":"英国银行股","BK4504":"桥水持仓","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","BBYY":"GraniteShares YieldBOOST BABA ETF","LU1823568750.SGD":"Fidelity Global Technology A-ACC SGD","LU1688375341.USD":"贝莱德中国灵活股票基金","06618":"京东健康","LU2148611432.USD":"AZ ALLOCATION BALANCED BRAVE \"AAZ\" (USDHDG) ACC","LU0797268264.HKD":"ALLIANZ TOTAL RETURN ASIAN EQUITY \"AT\" (HKD) ACC","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","BK4207":"综合性银行","BK4607":"DeepSeek概念股","BK4220":"综合零售","BK4524":"宅经济概念","LU1235294995.USD":"FIDELITY GLOBAL TECHNOLOGY \"A\" (USDHDG) ACC","BK4527":"明星科技股","LU1769817096.USD":"UBS (LUX) EQUITY SICAV - GLOBAL EMERG MARKETS OPPO \"P\" (USD) INC","IE00B0JY6N72.USD":"PINEBRIDGE GLOBAL EMERGING MARKETS FOCUS EQUITY \"A\" (USD) ACC","IE00BFMHRM44.USD":"NEUBERGER BERMAN GLOBAL EQUITY MEGATRENDS \"A\" (USD) ACC","BK4526":"热门中概股","LU1769817179.HKD":"UBS (LUX) EQUITY SICAV - GLOBAL EMERG MARKETS OPPO \"P\" (HKD) INC","LU1282648689.USD":"ALLIANZ TOTAL RETURN ASIAN EQUITY \"AMG\" (USD) INC","BK1515":"抗疫概念","LU0348816934.USD":"ALLIANZ TOTAL RETURN ASIAN EQUITY \"AT\" (USD)","BK4122":"互联网与直销零售","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","BK4575":"芯片概念","LU0047713382.USD":"BGF EMERGING MARKETS \"A2\" ACC","BK1502":"双十一","LU1051769294.HKD":"BGF EMERGING MARKETS EQUITY INCOME \"A6\"(HKDHDG) INC","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","LU2226246903.HKD":"ALLIANZ TOTAL RETURN ASIAN EQUITY \"AT4\" (HKD) ACC","BK1501":"阿里概念股","LU1048588211.SGD":"Blackrock Asian Dragon A2 SGD-H","BK1589":"北水核心资产","BK4579":"人工智能","BK4614":"Manus概念股","KBAB":"2倍做多BABA ETF-KraneShares","LU0072462343.USD":"贝莱德亚洲巨龙基金","BK1142":"互联网与直销零售","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","BK1189":"医疗保健技术","BK1617":"AI医疗","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","BK4137":"综合支持服务","LU1105468828.SGD":"Allianz Total Return Asian Equity AM DIS H2-SGD","LABU":"三倍做多标普生物-Direxion","XBI":"SPDR S&P Biotech ETF","BK1615":"港股-互联网","BK4581":"高盛持仓","LU0918141705.HKD":"ALLIANZ TOTAL RETURN ASIAN EQUITY \"AM\" (HKD) INC","BK4543":"AI","LU0106959298.USD":"UBS (LUX) EQUITY FUND - EMERGING MARKETS SUSTAINABLE LEADERS (USD) \"P\" (USD) ACC","BK4531":"中概回港概念","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","LU0821914370.USD":"贝莱德亚洲成长领袖A2","BK4534":"瑞士信贷持仓","LU0651947912.USD":"BGF EMERGING MARKETS EQUITY INCOME \"A5G\" (USD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","SGXZ86797644.SGD":"MAYBANK ASIAN GROWTH AND INCOME-I \"A\" (SGDHDG) INC","BK4535":"淡马锡持仓","BK4538":"云计算","LU0328353924.USD":"UBS (LUX) EQUITY SICAV - GLOBAL EMERGING MARKETS OPPORTUNITY (USD) \"P\" (USD) ACC","LU0051755006.USD":"摩根大通中国A (dist)","BK4548":"巴美列捷福持仓","LU0949170772.SGD":"Blackrock Global Equity Income A6 SGD-H","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU1003077747.HKD":"BGF GLOBAL EQUITY INCOME \"A6\" (HKDHDG) INC","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","LU0553294199.USD":"BGF GLOBAL EQUITY INCOME \"A5G\" (USD) INC","IE00BF5LJ272.USD":"Legg Mason Martin Currie - Global Emerging Markets A Acc USD"},"translate_title":"中国在线医疗平台今年的增长可能会正常化——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"86618":0.6,"06618":1.94,"HSBC":0.69,"00241":1.96,"BABW":0.6,"BBYY":0.6,"BABX":0.6,"LABU":0.6,"KBAB":0.6,"BABO":0.6,"XBI":0.6},"content_text":"0912 GMT - Strong growth posted by Chinese online healthcare platforms in the past two years could be softer this year, though it's unlikely to be a concern for Alibaba Health Information Technology and JD Health, say HSBC analysts in a note. Online platforms have been gaining drug sales market share as more sales are taking place outside of hospitals, they say. They expect the prescription outflow to sustain growth for these platforms. HSBC lifts its target price for Alibaba Health to HK$6.50 from HK$6.00, but maintains a hold rating as its current valuation has priced in the company's recent artificial-intelligence developments. It raises its target price for JD Health to HK$77.50 from HK$75.50 on updated foreign exchange updates and retains a buy rating. Alibaba Health closed at HK$6.14 while JD Health ended at HK$60.25. (megan.cheah@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 10, 2026 04:12 ET (09:12 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}